Evogene Ltd. logo
Evogene Ltd. EVGN
$ 0.81 -9.28%

Annual report 2024
added 02-21-2026

report update icon

Evogene Ltd. Book Value 2011-2026 | EVGN

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Evogene Ltd.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
14.8 M 28.7 M 56.1 M 76.3 M 56.9 M 60.2 M 50.3 M 69.4 M 87.3 M 104 M 116 M 125 M 48.3 M -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
125 M 14.8 M 68.7 M

Quarterly Book Value Evogene Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - 76.3 M - 87.5 M - 71.9 M - 61.1 M - 71.4 M - - - 58.7 M - - - 77.6 M - - - 96 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
96 M 58.7 M 75.1 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
49 M - 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
382 M - 1052.0 % $ 415 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
427 M $ 1.68 2.44 % $ 429 M britainBritain
Acer Therapeutics Acer Therapeutics
ACER
-16.8 M - 2.71 % $ 14 M usaUSA
Acasti Pharma Acasti Pharma
ACST
66.6 M - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
70.7 M - - $ 86.2 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
319 M $ 8.81 1.73 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
5.63 B - - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
715 M - - $ 1.01 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
253 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
34.9 M - -13.47 % $ 169 M franceFrance
Adagene Adagene
ADAG
50.5 M $ 3.26 0.62 % $ 183 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
35.5 M $ 3.28 -2.62 % $ 7.89 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.33 B - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
8.32 M - -18.52 % $ 27.3 M britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
750 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
234 M - 0.23 % $ 488 M usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
-6.78 M - -19.68 % $ 18.4 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
176 M - -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
11.8 M $ 0.79 -1.29 % $ 4.31 M chinaChina
Alpine Immune Sciences Alpine Immune Sciences
ALPN
179 M - - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
113 M - 4.14 % $ 49.1 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
2.71 M $ 0.88 -1.43 % $ 442 M israelIsrael
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
18.9 M - 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
3.36 M - -11.43 % $ 502 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
60.8 M - - $ 10.1 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-4.54 M - -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
10.7 M - -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
10.6 M - - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-163 M $ 224.42 -2.52 % $ 5 B danmarkDanmark
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
29.5 M - - $ 26.5 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
785 M - -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
60.2 M - 3.77 % $ 22.4 M usaUSA
AVROBIO AVROBIO
AVRO
94.7 M - 1083.1 % $ 745 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
94.9 M $ 4.13 0.12 % $ 352 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
13.2 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
5.36 M - -10.17 % $ 12.2 K usaUSA
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.36 2.27 % $ 14.8 M usaUSA
Aptinyx Aptinyx
APTX
38.3 M - -39.0 % $ 4.57 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
40.9 B - - $ 96.9 B britainBritain
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-24.2 M - 17.91 % $ 11.1 M usaUSA
Brickell Biotech Brickell Biotech
BBI
11.6 M - -5.38 % $ 6.06 M usaUSA
Codexis Codexis
CDXS
66.9 M $ 1.17 -0.85 % $ 85.9 M usaUSA
Athira Pharma Athira Pharma
ATHA
44.8 M - - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
19.4 B $ 110.12 -0.28 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
3.5 B $ 14.49 -0.75 % $ 4.48 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
39.9 M - 1.93 % $ 17.4 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
688 M - - $ 867 M germanyGermany